These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 923330)

  • 21. Para-aminosalicylic-acid (PAS) concentrations in the serum during treatment with various PAS preparations.
    CITRON KM; KUPER SW
    Tubercle; 1959 Dec; 40():443-52. PubMed ID: 13693755
    [No Abstract]   [Full Text] [Related]  

  • 22. [Clinical pharmacokinetics of para-aminosalicylic acid tablets].
    Miroshnichenko II; Sokolova GB; Mokhireva LV
    Antibiot Khimioter; 2009; 54(1-2):20-4. PubMed ID: 19499713
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Chemotherapy of tuberculosis with p-aminosalicylic acid; experimental studies on PAS and sodium-PAS blood level after administration].
    KOELZER PP; WEHR KH; GIESEN J
    Arztl Forsch; 1953 Jul; 7(7):I/336-44. PubMed ID: 13091943
    [No Abstract]   [Full Text] [Related]  

  • 24. Non-extractive fluorometric measurement of p-aminosalicylic acid in plasma by ion-pairing techniques and high-performance liquid chromatography.
    Honigberg IL; Stewart JT; Clark TC; Davis DY
    J Chromatogr; 1980 Feb; 181(2):266-71. PubMed ID: 7372759
    [No Abstract]   [Full Text] [Related]  

  • 25. [Formation of metabolites of benzoyl-para-amino-salicylic acid (C-14-B-PAS) in the rat liver and its excretion in the urine and bile].
    JEUNET F; LAUBER E; AEBI H
    Naunyn Schmiedebergs Arch Exp Pathol Pharmakol; 1962; 242():564-75. PubMed ID: 14451756
    [No Abstract]   [Full Text] [Related]  

  • 26. [The para-aminosalicylic acid (PAS) level of the venous blood in patients after the administration of various PAS preparations for pulmonary tuberculosis].
    Kreukniet J; Tasman A; Bangma PJ
    Ned Tijdschr Geneeskd; 1965 Sep; 109(38):1760-1. PubMed ID: 5317952
    [No Abstract]   [Full Text] [Related]  

  • 27. Independent of etozolin elimination of kidney function. Single dose experiments in patients with renal insufficiency.
    Knauf H; Hasenfuss G; Wais U; Schollmeyer P; Mutschler E
    Arzneimittelforschung; 1980; 30(10):1791-3. PubMed ID: 7192116
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Evaluation of Bayesian estimation to discriminate subpopulations of patients with altered pharmacokinetics using fragmentary data: a pilot study with pefloxacin.
    Bruno R; Rosier P; Iliadis A; Le Roux Y; Montay G; Frydman A; Gaillot J
    Eur J Drug Metab Pharmacokinet; 1991; Spec No 3():338-45. PubMed ID: 1820906
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Retarding effect of butazolidine on the elimination of PAS].
    CURCHOD B; CHENET C; VIELHAUER S
    Schweiz Z Tuberk; 1954; 11(3):175-84. PubMed ID: 13205179
    [No Abstract]   [Full Text] [Related]  

  • 30. Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
    Farrell GC; Cooksley WG; Hart P; Powell LW
    Gastroenterology; 1978 Oct; 75(4):580-8. PubMed ID: 710827
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-dose pharmacokinetics of cetirizine in patients with chronic liver disease.
    Horsmans Y; Desager JP; Hulhoven R; Harvengt C
    J Clin Pharmacol; 1993 Oct; 33(10):929-32. PubMed ID: 8227463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Liver disease caused by PAS: toxic manifestations of PAS].
    POLI M; CORDIE L
    Arch Sci Med (Torino); 1952 May; 93(5):391-424. PubMed ID: 12997344
    [No Abstract]   [Full Text] [Related]  

  • 33. [Acetylation phenotype and biotransformation of various drugs].
    Grygorowicz J; Januszko J
    Wiad Lek; 1987 Mar; 40(5):319-23. PubMed ID: 3303698
    [No Abstract]   [Full Text] [Related]  

  • 34. Determination of blood levels of para-aminosalicylic acid (PAS) in tuberculous patients treated with various PAS preparations.
    BANG HO; STRANDGAARD E
    Acta Tuberc Scand; 1957; 34(1-2):58-75. PubMed ID: 13508356
    [No Abstract]   [Full Text] [Related]  

  • 35. [Inhibition of PAS elimination by sulfalkylamides of benzoic acid].
    OSTERLOH G
    Dtsch Gesundheitsw; 1953 Apr; 8(14):413-7. PubMed ID: 13067773
    [No Abstract]   [Full Text] [Related]  

  • 36. The folate pathway is a target for resistance to the drug para-aminosalicylic acid (PAS) in mycobacteria.
    Rengarajan J; Sassetti CM; Naroditskaya V; Sloutsky A; Bloom BR; Rubin EJ
    Mol Microbiol; 2004 Jul; 53(1):275-82. PubMed ID: 15225321
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Colorimetric determination of 3-aminophenol in the sodium salt of 4-aminosalicylic acid (sodium-PAS)].
    KOWALCZYK-KANIEWSKA T
    Acta Pol Pharm; 1962; 19():341-4. PubMed ID: 14035239
    [No Abstract]   [Full Text] [Related]  

  • 38. [Paper electrophoretic study of binding of PAS with blood proteins].
    WIEDERMANN D; TOVAREK J
    Lek List; 1954 Jun; 9(12):270-1. PubMed ID: 13213205
    [No Abstract]   [Full Text] [Related]  

  • 39. Liver function and medroxyprogesterone acetate elimination in man.
    Rautio A
    Biomed Pharmacother; 1984; 38(4):199-204. PubMed ID: 6498308
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical analysis of protionamide and para-aminosalicylic acid induced hepatotoxicity in 129 cases].
    Ge QP; Wang QF; Duan HF; Wang J; Chu NH
    Zhonghua Jie He He Hu Xi Za Zhi; 2013 Oct; 36(10):737-40. PubMed ID: 24433800
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.